Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Mechanical ventricular assistance

Mechanical ventricular assistance encompasses systems that transfer blood from a cardiac chamber into the arterial circulation, replacing part of the work of a ventricle unable to provide adequate perfusion. The device does not necessarily eliminate the underlying heart disease: it changes loading conditions, supports blood flow and may allow organs impaired by heart failure to recover. Its effectiveness depends on the interaction between the pump, native heart, pulmonary circulation and systemic vasculature, not merely on the motor's nominal pumping capacity.

An LVAD, or left ventricular assist device, supports the left ventricle; an RVAD supports the right ventricle, whereas biventricular assistance supports both. Temporary systems are used for hours, days or weeks in acute conditions; durable systems are designed for prolonged support, potentially lasting several years. Venoarterial ECMO belongs to the broader category of mechanical circulatory support and includes an oxygenator, but it is not equivalent to an LVAD: in its peripheral configuration it can increase left ventricular afterload and require an additional unloading strategy. A total artificial heart is also distinct, because it replaces the ventricles rather than assisting the heart left in place.

Using a durable device may allow a patient to reach heart transplantation, overcome a potentially reversible contraindication to transplant candidacy, or receive long-term therapy when transplantation is inappropriate. In a selected minority, reverse remodeling allows support to be removed. These goals are not immutable categories: the clinical course may change and must be reassessed during follow-up, together with the patient's preferences.

Indications, candidate selection and timing of implantation

The main indication for a durable LVAD is advanced heart failure with severe functional limitation, recurrent hospitalizations, hypoperfusion or dependence on inotropes despite appropriate medical and interventional treatment. A markedly reduced ejection fraction, considered in isolation, is insufficient to establish an indication. It is necessary to determine whether pump failure genuinely compromises survival and quality of life, whether correctable alternatives exist, and whether the anticipated benefit of support exceeds the surgical risk and the complications of living with the device.

Heart disease may be ischemic, nonischemic dilated, inflammatory, toxic, genetic or due to other conditions. Etiology influences anatomy, potential for recovery and associated risks, but selection primarily considers the hemodynamic phenotype. A dilated, hypocontractile left ventricle differs technically from a small cavity in restrictive or hypertrophic cardiomyopathy. Infiltrative diseases, congenital heart disease and systemic disorders require dedicated assessments: the feasibility of implanting a pump does not in itself establish a clinical benefit.

The INTERMACS profiles describe heart failure severity along a spectrum ranging from critical shock, profile 1, to advanced but stable functional impairment, profile 7. Profile 2 denotes progressive deterioration despite inotropic support, profile 3 stability dependent on inotropes, and profile 4 symptoms at rest; profiles 5 and 6 distinguish limitations predominantly associated with activity. The classification helps communicate urgency and risk but does not replace assessment of congestion, perfusion, frailty and reversibility of organ injury.

Timing is crucial. Waiting until irreversible multiorgan dysfunction develops may eliminate the benefit of an LVAD; implanting it too early in a still well-compensated patient may expose them prematurely to infections, bleeding and device-related problems. In profound shock, temporary support may stabilize circulation and clarify the neurological and visceral prognosis before durable implantation. Transition from one technology to another is not automatic: it requires a clinically realistic pathway toward recovery, transplantation or prolonged assistance.

The history covers hospitalizations, medication doses and tolerability, arrhythmias, syncope, previous procedures, stroke, bleeding and infections. Dose reductions due to hypotension or renal insufficiency, increasing diuretic requirements and declining ability to perform daily activities may indicate progression even before hospitalization occurs. Examination documents nutritional status, peripheral perfusion, venous pressure, ascites, edema, pulmonary congestion and signs of vascular disease. The combination of systemic congestion and low cardiac output is particularly important for estimating right ventricular reserve.

Assessment of frailty distinguishes, as far as possible, a potentially reversible component related to heart failure from irreversible disability, neurological disease or comorbidities. Cancer with limited prognosis, uncontrolled systemic infection or devastating neurological injury may render treatment inappropriate. Renal and hepatic dysfunction must be interpreted in context: impairment caused by low output or congestion may improve, whereas advanced structural disease may persist despite restored blood flow. This distinction cannot appropriately be reduced to a single creatinine measurement.

The ability to manage power supplies, dressings, anticoagulation and alarms is part of candidacy assessment. Understanding, mental health, possible substance dependence, housing conditions and the support network should be evaluated, with corrective measures offered where possible. Availability of assistance should not be treated as a judgment about a person's worth, but as an operational requirement to be developed. Informed consent includes realistic expectations, the possibility of further hospitalizations, limitations on activities and scenarios in which support might no longer align with goals of care.

Devices, operating principles and pathophysiology

In the most common durable LVAD configuration, an inflow cannula draws blood from the left ventricular apex; a pump transfers it through an outflow graft anastomosed to the aorta. The driveline passes through the skin and connects the implanted component to an external controller and power sources. Blood still reaches the left ventricle through the right heart and lungs. For this reason, a functioning LVAD cannot indefinitely compensate for severely impaired filling caused by right ventricular failure.

Continuous-flow pumps have progressively replaced many bulky pulsatile systems. Axial-flow and centrifugal technologies differ in geometry, pressure–flow relationships, rotor suspension and interaction with blood. HeartMate 3 uses a fully magnetically levitated rotor and wide blood-flow pathways, with programmed speed changes. This modulation does not fully reproduce the pulsatile physiology of the native ventricle or eliminate every hemocompatibility-related event, but has substantially improved outcomes compared with the axial-flow device used as a comparator in the MOMENTUM 3 studies.

For temporary support, transvalvular microaxial pumps move blood from the left ventricle into the aorta, whereas other configurations drain the left atrium and return blood to the arterial circulation. Right-sided support may use a circuit from the right atrium to the pulmonary artery. Vascular access, flow rate, need for oxygenation, valve anatomy and potential for mobilization guide the choice. A mechanical aortic prosthesis, ventricular thrombus or severe vascular disease may preclude particular configurations; no single temporary system is optimal for every form of shock. Daily reassessment and an exit strategy are integral to treatment.

The output of a rotary pump depends on speed, filling and the pressure difference between its inlet and outlet. At constant speed, rising aortic pressure impedes flow; reduced venous return or right ventricular output limits the blood available. Higher revolutions per minute therefore do not guarantee better perfusion. If the ventricle is emptied beyond the available blood supply, its wall or septum may approach the cannula, causing suction events, flow instability and arrhythmias.

Ventricular unloading reduces left ventricular end-diastolic volume and pressure, wall stress and pulmonary congestion. Functional mitral regurgitation may diminish as ventricular geometry changes. Over time, improved perfusion and loading conditions may promote reverse remodeling and metabolic recovery; however, regression of dilatation alone does not demonstrate sufficient contractile recovery to remove the pump. Fibrosis, ischemic damage and persistent cellular abnormalities may limit reserve despite an apparently improved echocardiogram.

The right ventricle must accommodate the increased venous return made possible by systemic support. Lower pulmonary pressures may ease its workload, but septal displacement, perioperative injury, volume overload and tricuspid regurgitation may impair it. The outcome depends on the balance of these effects. Prevention of right ventricular failure after LVAD implantation therefore begins before surgery and continues during support optimization.

An aortic valve that remains closed for a long time may develop commissural changes and promote aortic regurgitation. If blood pumped into the aorta returns to the ventricle and is drawn back into the pump, a recirculation loop develops: device flow may appear satisfactory while effective systemic output declines. Intermittent valve opening is a useful goal when compatible with adequate unloading, but should not be pursued at the expense of perfusion or congestion control.

Contact with artificial surfaces, shear stress and reduced pulsatility alter coagulation and hemostasis. Platelet and coagulation activation, abnormalities of von Willebrand factor and bleeding susceptibility coexist. Thrombosis and bleeding are therefore not simply opposite risks that can be adjusted by increasing or decreasing one medication. Infection, blood pressure, cannula anatomy and pump function all contribute to this same biological balance.

Preimplantation investigations and risk assessment

Echocardiography characterizes ventricular size and function, valves, estimated pulmonary pressure, intracardiac thrombi and possible interchamber communications. Right ventricular function should be assessed using multiple parameters rather than relying on a single longitudinal measurement. Significant aortic regurgitation requires a concomitant management strategy because it would reduce the effectiveness of the support circuit; important mitral stenosis limits filling. A patent foramen ovale or atrial septal defect may become the site of a right-to-left shunt when the LVAD lowers left-sided pressure, causing hypoxemia.

Right heart catheterization measures atrial and pulmonary pressures, wedge pressure, cardiac output and vascular resistance. Right atrial pressure, its ratio to wedge pressure, the pulmonary artery pulsatility index and indices of right ventricular work may contribute to risk estimation. However, they depend on volume status, inotropes, ventilation and timing of measurement: no threshold reliably identifies everyone who will develop right ventricular failure. The response to decongestion and hemodynamic optimization may be more informative than an isolated value.

Cardiopulmonary exercise testing, when it can be performed safely, quantifies functional limitation and ventilatory response, complementing the assessment of advanced heart failure. It is not essential in unstable patients or those dependent on mechanical support. Walking capacity, strength and nutritional assessment help plan rehabilitation, while recent deterioration may carry prognostic weight not captured by peak oxygen consumption alone. Risk scores support rather than replace multidisciplinary judgment.

Blood tests include a complete blood count, kidney and liver function, electrolytes, coagulation, blood group and relevant infectious-disease testing. Investigating the causes of anemia and identifying active bleeding are essential before therapy that will require anticoagulation. Renal assessment considers functional trends, proteinuria and imaging when indicated; hepatic assessment distinguishes congestion from cirrhosis and portal hypertension. Even apparently normalized biochemical results after stabilization must be interpreted alongside organ structure and reserve.

Chest CT is particularly useful after previous procedures or when it is necessary to define aortic anatomy, retrosternal relationships and surgical approaches. Coronary angiography or other coronary tests address specific questions rather than being an automatic requirement identical for every candidate. Respiratory, vascular and neurological assessments are guided by history and risk. The goal is not to accumulate tests but to identify conditions affecting feasibility, technique, prognosis or the choice between isolated left-sided support and more complex strategies.

The final decision brings together cardiac surgery, heart failure cardiology, anesthesiology, intensive care and other required disciplines. The goal of support, transplant potential, risk of needing right-sided assistance, treatment of concomitant lesions and discharge pathway are defined. Information is shared with the patient and those they choose to involve. Reasonable candidacy requires not only the possibility of surviving the operation but also an anticipated benefit in subsequent life.

Implantation, perioperative management and support optimization

Surgery positions the pump and its connections to ensure unobstructed inflow and outflow without twists or unfavorable angulation. Orienting the cannula toward the ventricular cavity and mitral inflow reduces the risk of interference with the septum, wall and subvalvular apparatus. Graft length and course must account for changes in filling and the heart's final position. Transesophageal echocardiography helps verify the cannulas, right ventricular function, valves, shunts and air removal before final stabilization.

During the first hours, the priority is to achieve effective perfusion without excessive congestion. Blood pressure, urine output, lactate, venous oxygen saturation, drainage output, right ventricular function and device parameters are assessed. Hypotension may result from vasoplegia, bleeding, tamponade, right ventricular failure or inadequate filling: indiscriminately increasing speed will not correct all these conditions. Even a localized pericardial collection can compromise filling without the classic presentation of tamponade seen in a patient who has not undergone surgery.

Adjustment of pump speed aims for sufficient left ventricular unloading, balanced septal position, adequate flow and absence of suction. The goal is not to make the ventricle as small as possible. Echocardiography and, when indicated, invasive measurements help distinguish residual congestion, inadequate filling and valvular recirculation. Stepwise speed-increase protocols must be tailored to the device model and clinical conditions; values and slopes derived from one technology cannot automatically be transferred to another.

Antithrombotic therapy is initiated according to surgical hemostasis and thrombosis risk, following device-specific protocols. For maintenance treatment, vitamin K antagonists remain the established standard; for many continuous-flow LVADs, the usual INR target is 2.0–3.0, with adjustments justified by the device and individual events. Time in therapeutic range is more informative than a single measurement. Drug interactions, dietary changes, hepatic dysfunction and interruptions for procedures can rapidly disturb this balance.

The ARIES-HM3 trial showed that, in HeartMate 3 recipients treated with a vitamin K antagonist, avoiding aspirin reduced nonsurgical bleeding without worsening the composite hemocompatibility outcome. This finding does not authorize patients to stop medication on their own or extrapolate the regimen to every device; recent revascularization or other antithrombotic indications require specific assessment. Direct oral anticoagulants are under investigation and are not an automatically equivalent class-wide substitute for the regimen validated for each LVAD.

Treatment of residual heart failure continues after implantation. Diuretics and neurohormonal medications are adjusted according to blood pressure, kidney function, potassium and tolerability, aiming to control congestion and afterload and promote myocardial recovery where possible. Evidence for these drugs in mechanically assisted hearts does not fully match the evidence in heart failure without a device. Blood pressure control must avoid both hypertension and hypoperfusion: ISHLT guidelines generally indicate a mean arterial pressure of 75–90 mmHg, individualized and measured using an appropriate method.

Rehabilitation includes progressive mobilization, restoration of muscle strength, nutritional support and hands-on training. Before discharge, patients must demonstrate competence with the controller, batteries, backup power, hygiene and dressing changes, alarm recognition and contact with their center. The driveline must be protected from pulling and contamination. Advice on showering, physical activity, travel and returning to work depends on healing, device type and individual circumstances, not a universal timetable.

Follow-up, interpretation of parameters and recognition of complications

Longitudinal monitoring integrates symptoms, quality of life, weight, blood pressure, driveline examination, blood tests, echocardiography and device interrogation. Comparison with the patient's baseline is essential: a value within a seemingly usual range may represent an important change from previous weeks. Hemoglobin, LDH, kidney and liver function and INR help identify complications before instability or advanced organ injury develops.

The displayed flow on the controller of many LVADs is an estimate derived from power, speed and blood characteristics; it is not a direct measurement of total cardiac output. Blood ejected through the aortic valve by the ventricle and any aortic recirculation further modify the relationship between the display and perfusion. The pulsatility index also reflects multiple determinants and should not be interpreted as an exclusive measure of circulating volume. Parameter interpretation varies by device model.

Blood pressure measurement is particularly challenging when pulsatility is reduced. An oscillometric monitor may not yield a reliable result; the opening pressure obtained with Doppler approximates mean arterial pressure mainly in low-pulsatility conditions, whereas with a more pronounced pulse it may be closer to systolic pressure. Confusing these quantities may lead to inappropriate blood pressure treatment. Pulse oximetry can also be difficult: in a critical situation, clinical assessment and invasive measurements or blood gas analysis are used as needed.

A low-flow alarm may result from hypovolemia, bleeding, right ventricular failure, arrhythmia, hypertension or circuit obstruction. Abnormally increased power and evidence of hemolysis make it important to investigate device thrombosis, but thrombosis does not always produce the same pattern. Kinking, twisting or external compression of the outflow graft may reduce flow without marked hemolysis. Echocardiography, device log analysis and CT angiography are selected to locate the problem.

Mechanical destruction of red blood cells may be indicated by elevated LDH, plasma-free hemoglobin, anemia and dark urine. Low haptoglobin alone, common during continuous-flow support, does not establish an acute event. Confirmation requires a coherent set of findings and exclusion of other causes, including specimen hemolysis. A persistent rise from baseline merits attention even before the patient develops pronounced anemia.

LVAD-associated bleeding includes early surgical events and later bleeding, particularly from the gastrointestinal tract. Anticoagulation, von Willebrand factor abnormalities, vascular lesions and comorbidities may all contribute. Treatment must control the bleeding source and restore a sustainable antithrombotic regimen; repeated interruptions without a coordinated strategy introduce further risks. Melena, hematemesis, neurological deterioration and rapid hemoglobin decline require urgent assessment.

Driveline infection may remain superficial or spread along the tunnel and involve deeper components. Pain, erythema, discharge, fever or bacteremia require assessment of the extent of infection, not merely empiric local treatment. Prevention includes cable stabilization, proper dressing technique and avoidance of trauma. Persistent infection may complicate anticoagulation, transplant candidacy and support function.

Ventricular arrhythmias may initially be tolerated because of pump flow, but they are not harmless: they can reduce right ventricular output, cause syncope or impair LVAD filling. Ischemia, electrolyte abnormalities, suction and scar-related substrates are investigated; drug therapy, defibrillators and ablation are individualized. Atrial arrhythmias can worsen right ventricular function and exercise capacity. The absence of immediate circulatory collapse does not justify delaying assessment of a sustained arrhythmia.

Noncardiac procedures require coordinated planning of anticoagulation, hemostasis, pump power and monitoring. Whether to interrupt a vitamin K antagonist and provide parenteral bridging depends on the procedure, device and individual risk; the approach is not the same for every operation. Staff must understand the physiology of support and ensure uninterrupted device operation during transfers and anesthesia. Compatibility with tests and equipment, including magnetic resonance imaging, must be checked against the implanted system's instructions rather than assumed.

Emergency assessment takes into account that the peripheral pulse may be weak or absent even with effective circulation. Consciousness, breathing, perfusion, correctly measured blood pressure and device data are therefore central. Persistent alarms, syncope, neurological deficits, sudden dyspnea or signs of shock require activation of emergency care and coordination with the LVAD center. Speed, connections and controller must not be altered on an improvised basis; interruption of support may rapidly become dangerous.

Outcomes, myocardial recovery and long-term prognosis

Benefits include survival, functional capacity and symptom relief but must be considered alongside the burden of complications. In the five-year follow-up of MOMENTUM 3, estimated overall survival was 58.4% with the magnetically levitated pump and 43.7% with the axial-flow pump; the advantage also included survival free of disabling stroke or reoperation for device malfunction. These estimates describe the study population and its follow-up, not an individual prediction or a randomized comparison with transplantation.

Individual prognosis depends on biological age, right ventricular function, renal and hepatic reserve, frailty, infections, neurological events and the ability to maintain stable treatment. Survival without major disability does not necessarily mean living without hospitalizations. Independence, pain, sleep, sexuality, psychological health and the burden of care on the family also need discussion. Quality-of-life questionnaires and the patient's stated goals complement hemodynamic and laboratory data.

Myocardial recovery should be actively assessed in plausible candidates, particularly in certain nonischemic cardiomyopathies of shorter duration. RESTAGE-HF demonstrated the feasibility of a structured pathway of unloading, medical therapy and reassessment in a selected population. The success rate of that program does not represent the frequency of explantation among all LVAD recipients. The decision requires stable ventricular dimensions, function, pressures and output during supervised reduced-support testing, together with assessment of functional reserve.

Following any planned removal or deactivation of the device, remission requires surveillance: the underlying cardiomyopathy may persist and heart failure may recur. Medical therapy is also reassessed without assuming that normalization of ejection fraction represents definitive cure. When recovery is insufficient, support may continue as durable treatment or a bridge to transplantation, provided the benefit–risk balance remains favorable.

In patients with repeated complications, severe neurological injury or progression of uncorrectable disease, goals of care must be reconsidered. Palliative care can accompany active treatment from the time of candidacy and does not imply abandoning therapy. Any decision to limit or withdraw support requires an explicit clinical, ethical and care pathway consistent with patient wishes and applicable law. Quality of care is also measured by the ability to guide these decisions without abandoning the patient.

References
  1. Saeed D et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10-Year Update. Journal of Heart and Lung Transplantation. 2023;42(7):e1–e222.
  2. Bernhardt AM et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support. Journal of Heart and Lung Transplantation. 2023;42(4):e1–e64.
  3. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726.
  4. Crespo-Leiro MG et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;20(11):1505–1535.
  5. Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032.
  6. Cameli M et al. Multimodality imaging for the evaluation and management of patients with long-term (durable) left ventricular assist devices: A clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology. European Heart Journal – Cardiovascular Imaging. 2024;25(10):e217–e240.
  7. Uriel N et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. Journal of the American College of Cardiology. 2012;60(18):1764–1775.
  8. Hollis IB et al. An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device. Journal of Heart and Lung Transplantation. 2024;43(8):1199–1234.
  9. Mehra MR et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. New England Journal of Medicine. 2019;380(17):1618–1627.
  10. Mehra MR et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022;328(12):1233–1242.
  11. Mehra MR et al. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023;330(22):2171–2181.
  12. Birks EJ et al. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020;142(21):2016–2028.
  13. Peled Y et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024. Journal of Heart and Lung Transplantation. 2024;43(10):1529–1628.e54.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.